Breast Cancer

Treatment [vic]-trastuzumab duocarmazine improved progression-free survival for patients with pretreated, metastatic HER2-positive breast cancer when compared with physician’s choice chemotherapy.

Patients undergoing implant-based or autologous reconstruction and received adjuvant or neoadjuvant chemotherapy did not have an association with likelihood of complications compared with those who did not undergo chemotherapy.

Patients have higher odds of experiencing rapid relapse in triple-negative breast cancer if they have Medicaid or no insurance, are single, are Black, and have not undergone surgery.

Data collected from several large studies of women with breast cancer over the age of 65 years at diagnosis show how frequently certain known pathogenic variants occur in different patient subsets.

Latina breast cancer survivors are less likely to seek counseling due to concerns that the counselor will not understand their values or have linguistic challenges.

Survivorship incorporated into primary cancer care may be more cost effective and lead to better clinical and patient-reported outcomes in patients with breast cancer and other malignancies.

Patients with high-risk early breast cancer who received zoledronate for over 2 years did not experience an improvement in prognosis.

The FDA issues a warning regarding the use of robotically-assisted surgical devices for mastectomy procedures related to breast cancer.

This special episode of “Oncology Peer Review On-The-Go” features Lee Schwartzberg, MD, FACP discussing treatment patterns in HR-positive breast cancer with.

Analysis of women who have survived breast cancer reveal impacts on sexual life.

Research on NCCN resource-stratified guidelines for treating breast cancer could lead to overtreating patients in lower-middle and upper-middle income countries, while low-income populations could receive undertreatment.

This article reviews NCCN Guideline updates regarding the use of genomic assays in predicting the benefit of extended adjuvant endocrine therapy in patients with HR+ breast cancer and includes insights from Lee S. Schwartzberg, MD, of West Cancer Center at the University of Tennessee Health Science Center in Memphis, TN.

CancerNetwork’s latest podcast episode features a conversation with Anath Ravi, PhD, of MOLLI Surgical and Randy Miles, MD, MPH, of Massachusetts General Hospital on the risks and benefits of breast cancer screening for average-risk women under the age of 50 years.

Transgender individuals may be more likely to develop breast cancer than cisgender men; guidelines need to be established and institutions need to eliminate discrimination to encourage higher breast cancer screening rates for this population of patients, investigators said.

Sara A. Hurvitz, MD, and Steven E. Vogl, MD, discuss clinical implications of a recently published review of third-line therapy options for patients with HER2-positive metastatic breast cancer.

Sara A. Hurvitz, MD, and Steven E. Vogl, MD, highlight key concepts from a recently published review of third-line therapy options for patients with HER2-positive metastatic breast cancer.

CancerNetwork® sat down with Sara A. Hurvitz, MD, at the 2021 ASCO Annual Meeting to talk about multidisciplinary care with geriatrician oncologists and the use of age-based analyses for diagnosis and following up of metastatic triple-negative breast cancer.

The cost of treating and managing breast cancer will rise two-and-a-half times by 2030 due to expected increases in young women being diagnosed with metastatic disease.

Tumor size and grade appeared to be associated with long-term survival in patients with estrogen receptor–positive/ERBB2-negative breast cancer who have undergone treatment with tamoxifen.

Myriad Genetics’ RiskScore offers personalized polygenic breast cancer risk assessment to undiagnosed women of all ancestries.

The combination of trilaciclib plus chemotherapy has been granted a fast track designation by the FDA for the treatment of locally advanced metastatic triple-negative breast cancer.

The FDA supported Athenex to continue developing oral paclitaxel and encequidar for patients with metastatic breast cancer.

Patients who discontinued endocrine therapy early were more likely to have experienced significant mental, physical, and social adverse effects of treatment.

Differences in frequency of germline pathogenic variants were not seen in patient subsets by ethnicity when comparing 12 genes linked with breast cancer.

Approximately 270,000 women are diagnosed with breast cancer each year in the United States alone. While there is consensus among national organizations including the US Preventive Services Task Force, the American Cancer Society, and the American College of Radiology that routine mammography screening should be performed in women 50 years and older, there is debate about the benefit-to-harm ratio of routine screening in average-risk women aged between 40 and 49 years. In this review, we examine risks and benefits of routine breast cancer screening starting at age 40 at the individual level, followed by evaluation of the role of advanced imaging techniques in screening women on a population level.

Patients who received breast-conserving surgery followed by radiotherapy demonstrated superior outcomes compared with patients who received mastectomy, regardless of radiotherapy status.

Patients with early-stage breast cancer who have ultralow risk disease indicated by a 70-gene signature demonstrated an excellent survival prognosis regardless of clinical risk.

Venetoclax plus fulvestrant did not result in better outcomes compared to fulvestrant alone in previously treated patients who had locally advanced or metastatic estrogen receptor–positive, HER2-negative breast cancer.

Palbociclib plus fulvestrant maintained a clinically meaningful overall survival improvement compared to placebo plus fulvestrant after a median follow-up of 73.3 months in patients with HR-positive, HER2-negative advanced breast cancer.

Data from the OlympiA trial support olaparib use in certain patients with BRCA1/2–positive early breast cancer.